ArticleCureus2026
Pilli Kai Score: A Proposed Digital Twin Framework Integrating Radiomics and Biomarkers for Enhanced Lung Nodule Risk Stratification.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indeterminate pulmonary nodules are a frequent and challenging finding in both screening and incidental imaging. Existing clinical prediction models provide structured estimates of malignancy risk but remain limited in precision, particularly for patients with intermediate pre-test probability. This technical report proposes the Pilli Kai Score, a digital twin framework that integrates clinical variables, radiomic features, blood-based biomarkers, and positron emission tomography (PET) data into a unified probability estimate for malignancy. The framework outlines a multi-modal modeling strategy incorporating validated clinical predictors, standardized radiomics, biomarkers evaluated in pulmonary nodule populations, and PET categories when available. Prespecified validation targets include strong calibration across risk strata, an area under the receiver operating characteristic (ROC) curve exceeding 0.85, and a high negative predictive value to safely defer invasive procedures in benign disease, with comparative evaluation against established clinical models. No patient-level data are analyzed; instead, illustrative figures present the proposed workflow and anticipated performance benchmarks. If validated in multi-center studies, this framework could improve diagnostic accuracy, reduce avoidable interventions, and enable more personalized lung cancer care pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.